Table 6. References for studies on induction chemotherapy (continued).
| ICT | Study | Severe acute toxicity (grade 3–5) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author | Arms | Pts (no.) | N/V | Mucositis | Dysphagia | Leukopenia | Neutropenia | Tbcp | Anemia | Infection | Renal | Neuro | Skin | Ototoxic | Total toxic deaths | All | Diff in acute toxicity | ||
| ICT vs. Surg | Wolf et al. (25) | A. ICT –> RT | – | – | – | – | – | – | – | – | – | – | – | – | – | 5 | – | None reported | |
| B. Surg –> RT | – | – | – | – | – | – | – | – | – | – | – | – | – | 3 | – | ||||
| Lefebvre et al. (26) | A. ICT –> RT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. Surg –> RT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Forastiere et al. (3) | A. ICT –> RT | 168 | 14% | 20% | 19% | 52% (hematologic) | 5% | 2% | 4% | 10% | – | 5 | 66% | None reported | |||||
| B. CRT | 171 | 20% | 43% | 35% | 47% (hematologic) | 4% | 4% | 5% | 7% | – | 9 | 77% | |||||||
| C. RT alone | 171 | 0 | 24% | 19% | 3% (hematologic) | 1% | 0 | 0 | 9% | – | 5 | 47% | |||||||
| ICT vs. CRT alone | Haddad et al. (27) | A. ICT –> CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | |
| B. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Cohen et al. (28) | A. ICT –> CRT | 124 | 6%/3% | 51% | 12% | 26% | 3% | 3% | 7% | 11% | – | – | 18% | – | – | 47% | A>B, P=0.002 | ||
| B. CRT alone | 133 | 5%/2% | 47% | 15% | 11% | 2% | 2% | 3% | 14% | – | – | 24% | – | – | 24% | ||||
| Ghi et al., Abstract (30) | A. ICT –> CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Stokes et al. (31) | A. ICT –> CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Chen et al. (32) | A. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. ICT +/− RT/CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| C. ICT +/− RT/CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Ock et al. (33) | A. ICT –> CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Merlano et al., Ongoing (34) | A. ICT –> CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Not assessed | ||
| B. CRT alone | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||||
| Yang et al. (35) | A. ICT –> CRT | No report on acute adverse events. Eye damage significantly higher with CRT alone than ICT–>CRT (16% vs. 10%, P=0.03) | |||||||||||||||||
| B. CRT alone | |||||||||||||||||||
| Zhang et al. (36) | A. ICT –> CRT | 239 | 23% | 29% | – | 26% | 28% | 11% | 10% | 0 | 3% | – | 2% | 0 | – | 76% | None reported | ||
| B. CRT alone | 237 | 14% | 32% | – | 20% | 11% | 1% | 1% | 0 | 0% | – | 4% | 0 | – | 56% | ||||
ICT, induction chemotherapy; Pts, patients; N/V, nausea or vomiting; Tbcp, thrombocytopenia; Neuro, neurological; Diff, difference; Surg, surgery; TPF, docetaxel-platinum-5-fluorouracil (docetaxel 75 mg/m2 on day 1, cisplatin 75–100 mg/m2 on day 1, 5–fluorouracil 750–1,000 mg/m2 on days 1–4 as continuous infusion; 3–4 cycles on 21-day interval); PF, platinum-5-fluorouracil (cisplatin 80–100 mg/m2 given as rapid intravenous infusion followed by 5-fluorouracil 800–1,000 mg/m2/day continuous 24-hour infusion for 5 days; 2–4 cycles on 21-day interval); CRT, chemoradiation; RT, radiotherapy.